X1 Biotech

Biotechnology

Overview

X1 Biotech is advancing X101, a repurposed small-molecule RUNX1 inhibitor, through a capital-efficient rare-disease strategy to enable broader impact.

Funding and backers

Total raised
$235k
3 rounds on record
Latest round
$40k
Convertible Note · May 2026 · 5 mo ago
The money's age
Fresh money
5 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 20 Raised a round Convertible Note $40k · SEC Form D May 8, 2025 Raised a round Convertible Note $95k · SEC Form D Nov 7, 2023 Raised a round Venture round $100k · SEC Form D
Funding rounds
RoundDateAmountInvestorsSource
Convertible Note May 2026 $40k — SEC Form D
Convertible Note May 2025 $95k — SEC Form D
Venture round Nov 2023 $100k — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity X1 Biotech Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Lawrence KaufmanExecutive OfficerSEC Form D
Michael AcetiExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
HealxVenture round · 5 mo ago · Founded 2014 · 201-500 employees · 1 role
Healx is a Cambridge company founded in 2014 that uses artificial intelligence to find treatments for rare diseases. Its knowledge graph…
Swivel, The Capital Efficient Protocol For Tokenized Cash-Flows.
Innovation and effectiveness for the treatment of rare and ultra-rare diseases.
Light Horse is a small molecule drug discovery company that is leading the way in a.
Magnet Biomedicine is advancing monovalent molecular glue inhibitors (MGIs) and innovative protein degraders to engage disease drivers.
Explore the Kyntra Bio site to learn about our oncology and rare disease therapies, pipeline highlights, clinical trials, culture, and…

Financials

Total raised
$235k
Latest round
Convertible Note
Funding rounds
3
Funding rounds
Round Announced Amount
Convertible Note 2026 $40k Details
Convertible Note 2025 $95k Details
Venture - Series Unknown 2023 $100k Details

People

Lawrence Kaufman
Executive Officer
Michael Aceti
Executive Officer
Leo Kim
Director
Dean Eliott
Director
Joseph Arboleda-Velasquez
Director
Neal Chen
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Needham United States
HQ